Compare Kraft Heinz Co (KHC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Mesoblast Limited — how do they compare? Kraft Heinz Co trades at $25.82 (market cap $30.66B), while Mesoblast Limited trades at $16.25 (market cap $2.17B). The key difference: Kraft Heinz Co is far larger — about 14.1× Mesoblast Limited's market cap, and Kraft Heinz Co pays a 6.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KHC | MESO | |
|---|---|---|
Market Cap | $30.66B | $2.17B |
Sector | Consumer Staples | Technology |
52-Week High | $28.94 | $20.96 |
52-Week Low | $21.21 | $12.88 |
Enterprise Value | $47.71B | $2.17B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $26.05, up 0.66% today, with a bullish technical signal and recent earnings beats. The stock shows strong operating cash flow of $4.46B in 2025 but faces profitability challenges with a net income margin of -23.05%. Analysts are mixed, with 57% holding a neutral stance, while the company's reorganization aims to spur growth. The dividend yield remains attractive at approximately 6.4%, supported by solid cash generation.
Outlook: KHC offers value with a low P/B of 0.73 and high dividend, but risks include persistent net losses and high debt. The upcoming Q2 2026 earnings on August 5 will be critical for confirming turnaround progress. Investors should weigh the dividend stability against fundamental weaknesses in a competitive food sector.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
